Literature DB >> 30037802

Prediction of cardiovascular disease among hematopoietic cell transplantation survivors.

Saro H Armenian1, Dongyun Yang2, Jennifer Berano Teh1, Liezl C Atencio1, Alicia Gonzales1, F Lennie Wong1, Wendy M Leisenring3, Stephen J Forman4, Ryotaro Nakamura4, Eric J Chow3.   

Abstract

Cardiovascular disease (CVD) is a leading cause of late morbidity and mortality in hematopoietic cell transplantation (HCT) survivors. HCT-specific CVD risk prediction models are needed to facilitate early screening and prevention. In the current study, patients who underwent HCT at City of Hope (COH) and survived 1-year free of clinically evident CVD (N = 1828) were observed for the development of heart failure (HF) or coronary artery disease (CAD) by 10-years from index date (1 year from HCT). CVD occurred in 135 individuals (92 HF, 43 CAD). Risk prediction models were developed for overall CVD (HF and/or CAD) using COH-derived integer risk scores. Risk scores based on selected variables (age, anthracycline dose, chest radiation, hypertension, diabetes, smoking) achieved an area under the curve (AUC) and concordance (C) statistic of 0.74 and 0.72 for CVD; these varied from 0.70 to 0.82 according to CVD subtype (HF or CAD). A Fred Hutchinson Cancer Research Center case cohort (N = 580) was used to validate the COH models. Validation cohort AUCs ranged from 0.66 to 0.75. Risk scores were collapsed to form statistically distinct low-, intermediate-, and high-risk groups, corresponding to 10-year cumulative incidences of CVD of 3.7%, 9.9%, and 26.2%, respectively. Individuals in the high- and intermediate-risk groups were at 7.8-fold (95% confidence interval, 5.0-12.2) and 2.9-fold (95% confidence interval, 1.9-4.6) risk of developing CVD (referent group: low risk). These validated models provide a framework on which to modify current screening recommendations and for the development of targeted interventions to reduce the risk of CVD after HCT.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 30037802      PMCID: PMC6058239          DOI: 10.1182/bloodadvances.2018019117

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  56 in total

1.  Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.

Authors:  Can-Lan Sun; Liton Francisco; Toana Kawashima; Wendy Leisenring; Leslie L Robison; K Scott Baker; Daniel J Weisdorf; Stephen J Forman; Smita Bhatia
Journal:  Blood       Date:  2010-07-23       Impact factor: 22.113

2.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Philip Greenland; Joseph S Alpert; George A Beller; Emelia J Benjamin; Matthew J Budoff; Zahi A Fayad; Elyse Foster; Mark A Hlatky; John McB Hodgson; Frederick G Kushner; Michael S Lauer; Leslee J Shaw; Sidney C Smith; Allen J Taylor; William S Weintraub; Nanette K Wenger; Alice K Jacobs
Journal:  Circulation       Date:  2010-11-15       Impact factor: 29.690

3.  A Fitbit and Facebook mHealth intervention for promoting physical activity among adolescent and young adult childhood cancer survivors: A pilot study.

Authors:  Jason A Mendoza; K Scott Baker; Megan A Moreno; Kathryn Whitlock; Mark Abbey-Lambertz; Alan Waite; Trina Colburn; Eric J Chow
Journal:  Pediatr Blood Cancer       Date:  2017-06-15       Impact factor: 3.167

4.  Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.

Authors:  N S Majhail; J D Rizzo; S J Lee; M Aljurf; Y Atsuta; C Bonfim; L J Burns; N Chaudhri; S Davies; S Okamoto; A Seber; G Socie; J Szer; M T Van Lint; J R Wingard; A Tichelli
Journal:  Hematol Oncol Stem Cell Ther       Date:  2012

5.  Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts.

Authors:  James A de Lemos; Colby R Ayers; Benjamin D Levine; Christopher R deFilippi; Thomas J Wang; W Gregory Hundley; Jarett D Berry; Stephen L Seliger; Darren K McGuire; Pamela Ouyang; Mark H Drazner; Matthew Budoff; Philip Greenland; Christie M Ballantyne; Amit Khera
Journal:  Circulation       Date:  2017-03-30       Impact factor: 29.690

6.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report.

Authors:  Saro H Armenian; Wassim Chemaitilly; Marcus Chen; Eric J Chow; Christine N Duncan; Lee W Jones; Michael A Pulsipher; Alan T Remaley; Alicia Rovo; Nina Salooja; Minoo Battiwalla
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-30       Impact factor: 5.742

7.  Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors.

Authors:  Kasey J Leger; Kara Cushing-Haugen; John A Hansen; Wenhong Fan; Wendy M Leisenring; Paul J Martin; Lue Ping Zhao; Eric J Chow
Journal:  Biol Blood Marrow Transplant       Date:  2016-03-08       Impact factor: 5.742

Review 8.  Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.

Authors:  Eric J Chow; Lynnette Anderson; K Scott Baker; Smita Bhatia; Gregory M T Guilcher; Jennifer T Huang; Wendy Pelletier; Joanna L Perkins; Linda S Rivard; Tal Schechter; Ami J Shah; Karla D Wilson; Kenneth Wong; Satkiran S Grewal; Saro H Armenian; Lillian R Meacham; Daniel A Mulrooney; Sharon M Castellino
Journal:  Biol Blood Marrow Transplant       Date:  2016-01-21       Impact factor: 5.742

Review 9.  Cardiovascular disease in survivors of hematopoietic cell transplantation.

Authors:  Saro H Armenian; Eric J Chow
Journal:  Cancer       Date:  2013-10-25       Impact factor: 6.860

10.  Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.

Authors:  Saro H Armenian; Melissa M Hudson; Ming Hui Chen; Steven D Colan; Lanie Lindenfeld; George Mills; Aida Siyahian; Sarah Gelehrter; Ha Dang; Wendy Hein; Daniel M Green; Leslie L Robison; F Lennie Wong; Pamela S Douglas; Smita Bhatia
Journal:  BMC Cardiovasc Disord       Date:  2016-10-04       Impact factor: 2.298

View more
  17 in total

Review 1.  Cardiovascular risk assessment and management of patients undergoing hematopoietic cell transplantation.

Authors:  Guilherme H Oliveira; Sadeer G Al-Kindi; Avirup Guha; Amit K Dey; Isaac B Rhea; Marcos J deLima
Journal:  Bone Marrow Transplant       Date:  2020-10-31       Impact factor: 5.483

2.  Conditional Survival, Cause-Specific Mortality, and Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation.

Authors:  F Lennie Wong; Jennifer Berano Teh; Liezl Atencio; Tracey Stiller; Heeyoung Kim; Dayana Chanson; Stephen J Forman; Ryotaro Nakamura; Saro H Armenian
Journal:  J Natl Cancer Inst       Date:  2020-11-01       Impact factor: 13.506

3.  Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.

Authors:  John E Levine; Joseph H Antin; Carl E Allen; Lauri M Burroughs; Kenneth R Cooke; Steven Devine; Helen Heslop; Ryotaro Nakamura; Julie An Talano; Gregory Yanik; Nancy DiFronzo
Journal:  Biol Blood Marrow Transplant       Date:  2020-02-05       Impact factor: 5.742

Review 4.  Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.

Authors:  Nicholas S Wilcox; Seth J Rotz; McKay Mullen; Evelyn J Song; Betty Ky Hamilton; Javid Moslehi; Saro H Armenian; Joseph C Wu; June-Wha Rhee; Bonnie Ky
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

5.  How I treat cardiovascular complications in patients with lymphoid malignancies.

Authors:  Joerg Herrmann; Kristen B McCullough; Thomas M Habermann
Journal:  Blood       Date:  2022-03-10       Impact factor: 25.476

6.  Comparison of the impact of two post-remission therapy regimens on cardiac events in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Jin Hayakawa; Hideki Nakasone; Daisuke Minakata; Shin-Ichiro Fujiwara; Ayumi Gomyo; Yu Akahoshi; Yusuke Komiya; Naonori Harada; Tomotaka Ugai; Kazuaki Kameda; Hidenori Wada; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Miki Sato; Kiriko Terasako-Saito; Misato Kikuchi; Shun-Ichi Kimura; Junya Kanda; Shinichi Kako; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2022-04-16       Impact factor: 2.319

Review 7.  Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation.

Authors:  Seth J Rotz; Thomas D Ryan; Salim S Hayek
Journal:  J Thromb Thrombolysis       Date:  2020-11-24       Impact factor: 2.300

Review 8.  Cardiovascular Issues in Hematopoietic Stem Cell Transplantation (HSCT).

Authors:  Teresa López-Fernández; Irene Sánchez Vadillo; Ana López de la Guía; Karem Humala Barbier
Journal:  Curr Treat Options Oncol       Date:  2021-04-30

Review 9.  Cardiac complications associated with hematopoietic stem-cell transplantation.

Authors:  Akihiro Ohmoto; Shigeo Fuji
Journal:  Bone Marrow Transplant       Date:  2021-08-11       Impact factor: 5.174

Review 10.  Clonal Hematopoiesis of Indeterminate Potential as a Novel Risk Factor for Donor-Derived Leukemia.

Authors:  Sarah S Burns; Reuben Kapur
Journal:  Stem Cell Reports       Date:  2020-08-11       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.